Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/DYRK1A_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/DYRK1A_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/DYRK1A_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/DYRK1A_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/DYRK1A_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/DYRK1A_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/DYRK1A_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/DYRK1A_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/DYRK1A_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/DYRK1A_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000039817 | Prostate | BPH | mRNA splicing, via spliceosome | 112/3107 | 320/18723 | 6.21e-16 | 1.07e-13 | 112 |
GO:004802418 | Prostate | BPH | regulation of mRNA splicing, via spliceosome | 51/3107 | 101/18723 | 3.74e-15 | 5.26e-13 | 51 |
GO:004325418 | Prostate | BPH | regulation of protein-containing complex assembly | 133/3107 | 428/18723 | 5.40e-14 | 6.08e-12 | 133 |
GO:007233118 | Prostate | BPH | signal transduction by p53 class mediator | 64/3107 | 163/18723 | 3.51e-12 | 2.82e-10 | 64 |
GO:005125818 | Prostate | BPH | protein polymerization | 96/3107 | 297/18723 | 1.52e-11 | 1.10e-09 | 96 |
GO:004851110 | Prostate | BPH | rhythmic process | 96/3107 | 298/18723 | 1.88e-11 | 1.31e-09 | 96 |
GO:003227118 | Prostate | BPH | regulation of protein polymerization | 80/3107 | 233/18723 | 2.67e-11 | 1.78e-09 | 80 |
GO:000762310 | Prostate | BPH | circadian rhythm | 73/3107 | 210/18723 | 1.02e-10 | 6.02e-09 | 73 |
GO:003311918 | Prostate | BPH | negative regulation of RNA splicing | 18/3107 | 25/18723 | 1.28e-09 | 5.57e-08 | 18 |
GO:000038010 | Prostate | BPH | alternative mRNA splicing, via spliceosome | 35/3107 | 77/18723 | 2.89e-09 | 1.13e-07 | 35 |
GO:000038110 | Prostate | BPH | regulation of alternative mRNA splicing, via spliceosome | 29/3107 | 60/18723 | 1.16e-08 | 3.81e-07 | 29 |
GO:190331218 | Prostate | BPH | negative regulation of mRNA metabolic process | 38/3107 | 92/18723 | 1.63e-08 | 5.11e-07 | 38 |
GO:190179618 | Prostate | BPH | regulation of signal transduction by p53 class mediator | 38/3107 | 93/18723 | 2.31e-08 | 6.99e-07 | 38 |
GO:190290410 | Prostate | BPH | negative regulation of supramolecular fiber organization | 55/3107 | 167/18723 | 1.60e-07 | 3.63e-06 | 55 |
GO:00506868 | Prostate | BPH | negative regulation of mRNA processing | 17/3107 | 29/18723 | 3.61e-07 | 7.60e-06 | 17 |
GO:003033016 | Prostate | BPH | DNA damage response, signal transduction by p53 class mediator | 30/3107 | 72/18723 | 4.09e-07 | 8.44e-06 | 30 |
GO:00705076 | Prostate | BPH | regulation of microtubule cytoskeleton organization | 48/3107 | 148/18723 | 1.57e-06 | 2.67e-05 | 48 |
GO:00480258 | Prostate | BPH | negative regulation of mRNA splicing, via spliceosome | 13/3107 | 20/18723 | 1.72e-06 | 2.88e-05 | 13 |
GO:003133316 | Prostate | BPH | negative regulation of protein-containing complex assembly | 44/3107 | 141/18723 | 1.28e-05 | 1.70e-04 | 44 |
GO:005149410 | Prostate | BPH | negative regulation of cytoskeleton organization | 49/3107 | 163/18723 | 1.32e-05 | 1.74e-04 | 49 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DYRK1A | SNV | Missense_Mutation | | c.217G>C | p.Asp73His | p.D73H | Q13627 | protein_coding | deleterious(0) | benign(0.364) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
DYRK1A | SNV | Missense_Mutation | | c.1744C>G | p.His582Asp | p.H582D | Q13627 | protein_coding | tolerated_low_confidence(0.18) | possibly_damaging(0.84) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
DYRK1A | SNV | Missense_Mutation | | c.1976N>T | p.Ser659Phe | p.S659F | Q13627 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.962) | TCGA-A8-A094-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DYRK1A | SNV | Missense_Mutation | | c.1626C>A | p.Phe542Leu | p.F542L | Q13627 | protein_coding | tolerated(0.05) | benign(0.001) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
DYRK1A | SNV | Missense_Mutation | | c.161N>T | p.Ser54Phe | p.S54F | Q13627 | protein_coding | deleterious_low_confidence(0.01) | benign(0.044) | TCGA-AO-A0JC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
DYRK1A | SNV | Missense_Mutation | | c.46C>T | p.Arg16Trp | p.R16W | Q13627 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.454) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
DYRK1A | SNV | Missense_Mutation | | c.492G>C | p.Leu164Phe | p.L164F | Q13627 | protein_coding | deleterious(0.02) | probably_damaging(0.949) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
DYRK1A | SNV | Missense_Mutation | | c.2230N>C | p.Asp744His | p.D744H | Q13627 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.99) | TCGA-BH-A18P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
DYRK1A | SNV | Missense_Mutation | | c.183G>C | p.Gln61His | p.Q61H | Q13627 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.626) | TCGA-D8-A1JP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
DYRK1A | SNV | Missense_Mutation | | c.1898A>G | p.Tyr633Cys | p.Y633C | Q13627 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.984) | TCGA-E2-A15E-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | | PMID28766366-Compound-Scheme1WO2011135259 | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | | PMID28766366-Compound-Scheme15-1 | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | | PMID28766366-Compound-Scheme6Pyrrolo[2,3-d]pyrimidines | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | | PMID28766366-Compound-Scheme23MPPDerivatives | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | inhibitor | 249565842 | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | | PMID28766366-Compound-Scheme13INDY | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | inhibitor | 405560505 | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | | PMID28766366-Compound-Scheme4Upper | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | | PMID28766366-Compound-Scheme12-3 | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | | PMID28766366-Compound-Scheme18 | | |